Related Experiment Videos
Optimal management of older patients with atrial fibrillation
1Hebrew Hospital Home, New York, New York.
Insights
Elderly patients with atrial fibrillation at high risk for stroke should receive warfarin. Those with contraindications or low risk may use aspirin, while rapid rates require immediate intervention with specific medications or cardioversion.
Area of Science:
- Cardiology
- Geriatrics
- Pharmacology
Background:
- Atrial fibrillation (AF) is a common arrhythmia in the elderly, increasing stroke risk.
- Management strategies for AF vary based on patient risk factors, comorbidities, and arrhythmia characteristics.
Purpose of the Study:
- To outline optimal therapeutic strategies for managing atrial fibrillation in elderly patients.
- To provide guidance on stroke prevention, rate control, and rhythm management in AF.
Main Methods:
- Review of current guidelines and evidence for AF management.
- Discussion of pharmacologic and non-pharmacologic treatment options, including anticoagulation, rate-controlling agents, and cardioversion.
Main Results:
- Warfarin is recommended for high-risk elderly AF patients without contraindications.
- Aspirin is an alternative for low-risk patients or those with contraindications to anticoagulation.
- Immediate cardioversion or rate-controlling medications (verapamil, diltiazem, beta-blockers) are indicated for rapid ventricular rates with hemodynamic compromise.
Conclusions:
- Tailored management of atrial fibrillation is crucial, considering individual patient profiles.
- Beta-blockers are valuable for ventricular rate control and post-conversion rhythm stabilization.
- Amiodarone may be considered for refractory symptomatic AF.
Abstract:
Long term oral warfarin should be administered to elderly patients with atrial fibrillation who are at high risk for developing thromboembolic stroke and who have no contraindications to anticoagulant therapy. Oral aspirin (acetylsalicylic acid) 325mg daily may be given to elderly patients with chronic atrial fibrillation who have contraindications to anticoagulant therapy or who are not at high risk for developing thromboembolic stroke. Management of atrial fibrillation includes treatment of the underlying disease and precipitating factors. If patients have paroxysmal atrial fibrillation with a very rapid ventricular rate associated with hypotension, severe left ventricular failure or chest pain due to myocardial ischaemia, immediate direct-current cardioversion should be performed. Intravenous verapamil, diltiazem or a beta-blocker should be used for immediate slowing of a very rapid ventricular rate associated with atrial fibrillation. If a rapid ventricular rate associated with atrial fibrillation persists at rest or during exercise despite digoxin, then oral verapamil, diltiazem or a beta-blocker should be added. Low dosages of oral amiodarone (200 to 400 mg/day) may be used in selected patients with symptomatic life-threatening atrial fibrillation refractory to other therapy. No medication which depresses atrioventricular conduction should be given to patients with atrial fibrillation and a slow ventricular rate. Cardioversion should not be performed in asymptomatic elderly patients with chronic atrial fibrillation. This author would use a beta-blocker for control of ventricular arrhythmias and following conversion of atrial fibrillation to sinus rhythm. Should atrial fibrillation recur, beta-blockers have the additional advantage of slowing the ventricular rate.